BlackRock, Inc. 13D and 13G filings for Atara Biotherapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-07-08 4:32 pm Sale |
2024-06-30 | 13G | Atara Biotherapeutics, Inc. ATRA |
BlackRock Inc. BLK |
0 0.000% |
-283,489 (Position Closed) |
Filing |
| 2024-01-26 5:25 pm Sale |
2023-12-31 | 13G | Atara Biotherapeutics, Inc. ATRA |
BlackRock Inc. BLK |
283,489 7.000% |
-82,597 (-22.56%) |
Filing |
| 2023-01-24 1:56 pm Purchase |
2022-12-31 | 13G | Atara Biotherapeutics, Inc. ATRA |
BlackRock Inc. BLK |
366,086 9.600% |
53,424 (+17.09%) |
Filing |
| 2022-02-03 4:41 pm Purchase |
2021-12-31 | 13G | Atara Biotherapeutics, Inc. ATRA |
BlackRock Inc. BLK |
312,662 8.800% |
54,485 (+21.10%) |
Filing |
| 2021-01-28 5:56 pm Purchase |
2020-12-31 | 13G | Atara Biotherapeutics, Inc. ATRA |
BlackRock Inc. BLK |
258,177 7.800% |
74,960 (+40.91%) |
Filing |